BioCryst Pharmaceuticals (NASDAQ:BCRX) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Tuesday, Benzinga reports. The firm currently has a $12.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Down 0.2 %

NASDAQ BCRX opened at $5.26 on Tuesday. The stock has a market capitalization of $1.09 billion, a PE ratio of -4.46 and a beta of 1.96. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.96. The company has a 50 day moving average price of $4.90 and a two-hundred day moving average price of $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.28) EPS. As a group, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares during the last quarter. Teacher Retirement System of Texas increased its position in BioCryst Pharmaceuticals by 4.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after buying an additional 2,519 shares during the period. Fifth Third Bancorp lifted its holdings in shares of BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the last quarter. Teza Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 12.8% in the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 4,180 shares during the period. Finally, Great Valley Advisor Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 34.7% in the third quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 4,200 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.